Mylan's (MYL) EpiPen Settlement is Credit-Negative Development - Moody's

October 10, 2016 3:26 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Moody's Investors Service commented that Mylan's (Nasdaq: MYL) settlement with the US Department of Justice and other government agencies to resolve EpiPen's reimbursement classification with the Centers for Medicaid and Medicare Services is a credit negative development. There are no changes to Mylan N.V.'s Baa3 rating or the stable ratings outlook.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Credit Ratings

Related Entities

Moody's Investors Service

Add Your Comment